Objectives: Bacterial biofilms developing in the bronchial tree of patients experiencing acute exacerbations of chronic bronchitis (AECBs) are suggested to cause relapses and recurrences of the disease because the matrix barrier impairs antibiotic access to the offending organisms. We examined whether bronchodilators could modulate pneumococcal biofilm development and antibiotic action using an in vitro model.
Introduction
Streptococcus pneumoniae is one of the main pathogens associated with acute exacerbations of chronic bronchitis (AECBs). 1, 2 Its capacity to form biofilms favours its persistence in the airways 3 and is likely to contribute to chronic colonization 4, 5 leading to recurrences and/or relapses. 6 Within biofilms, bacteria are embedded in an extracellular matrix made of polymeric substances that creates a diffusion barrier to antibiotics, thereby reducing their activity. 4, 7, 8 For these reasons, destructuring the biofilm matrix could be an appealing strategy to improve antibiotic effectiveness, 9 -12 even though the mechanism of action of the substances used in this context may be unrelated to their expected primary pharmacological activity. 13 Patients with COPD usually receive bronchodilators. Ipratropium (a muscarinic antagonist that does not inhibit mucociliary clearance from bronchi) 14 and salbutamol (a selective b 2 -agonist, with minimal untoward effects on cardiac rhythm, especially if given by inhalation) 15 are both recommended as short-acting bronchodilators for use in first-line therapy. 16 Beyond their primary and well-established relaxing effects on bronchial smooth muscles, 17 we wondered whether these drugs could also act by modifying the development of pneumococcal biofilms and their susceptibility to antibiotics, but could find no relevant published data. We therefore decided to address this issue directly by taking advantage of the recent development of an in vitro pharmacodynamic model of S. pneumoniae biofilms in which the activity of antibiotics against biofilms can be quantified with respect to both bacterial viability and biomass. 18 This model enabled us to observe that S. pneumoniae isolates from AECB patients easily produce both naive and induced biofilms (reflecting primary infection and secondary colonization, respectively). 19 In the present study, we first screened clinical isolates from the sputum of patients admitted to hospital with a confirmed diagnosis of AECBs for their capacity to produce biofilm in vitro. 18 Having observed no significant differences in biofilm formation between these clinical isolates and two reference strains, we focused on these reference strains and one selected clinical isolate to investigate the influence exerted by ipratropium and salbutamol on biofilm growth. For antibiotics, we first selected amoxicillin and clarithromycin as representatives of b-lactams and macrolides, respectively, and commonly recommended for patients with AECBs. 16 We then moved to moxifloxacin (because of its reported higher efficacy in the treatment of AECBs compared with other antibiotics) 20, 21 and to solithromycin, a new fluoroketolide 22, 23 active against contemporary macrolide-resistant strains 19, 24 and currently in Phase III clinical development for the treatment of lower respiratory tract infections, in comparison with moxifloxacin. 25 These two antibiotics have also been shown to be the most effective within their respective class in the in vitro model used here. 18 We show here that ipratropium causes massive destructuring of biofilms associated with a marked increase in activity of moxifloxacin and, to a lesser extent, solithromycin. Likewise, salbutamol also increases the activity of these two antibiotics, probably by stimulating bacterial neuraminidase activity, since most of its effects were antagonized by zanamivir, originally designed as an inhibitor of the influenza neuraminidase 26 but which also acts on pneumococcal neuraminidase A (NanA). 27 
Materials and methods

AECB patients and correlations between medication and severity factors
Forty-seven S. pneumoniae isolates were collected from patients with: (i) confirmed AECB diagnosis (Anthonisen's criteria); 28 (ii) a specimen fulfilling the interpretive criteria for lower respiratory tract origin; 29 (iii) need of hospitalization; and (iv) anamnestic confirmation of recent or current bronchodilator use. Data were thereafter anonymized. Tables S1 and S2 (available as Supplementary data at JAC Online) show the patients' main demographic, environmental and medical characteristics and the associations between pre-hospitalization medications and markers of disease severity. In brief, patients were almost equally distributed within the age groups of 55-64, 65-74 and ≥75 years. Comorbidities [diabetes, lung cancer (primary or with metastases), alcoholism, psychiatric disorders, hypertension] were frequent. Most patients were men and lived at home prior to hospitalization, and 60% were active smokers. Incidences of obstruction severity according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) scores 16 were almost equally distributed between low (1 or 2) and high (3 or 4) levels. Use of b 2 -agonists, muscarinic antagonists, long-acting bronchodilators and inhaled corticoids prior to hospitalization were significantly associated with higher COPD severity (GOLD score 3 or 4) upon admission and prolonged hospitalization (.10 days). Short-acting bronchodilator intake was associated with high obstruction severity. The protocol for sample collection and subsequent analysis, and for access to the corresponding medical files, was approved by the ad hoc committees of our university and of the contributing clinical centres (unique Belgian number 40320109783).
Strains: origin, culture and antibiotic susceptibility testing S. pneumoniae reference strains ATCC 49619 (capsulated, serotype 19F; used as international reference for pneumococcal susceptibility testing 30 ) and R6 (non-capsulated; often used for in vitro studies of pneumococcal biofilm architecture 31 and of the implication of NanA in biofilm formation 32 ) were purchased from ATCC (Manassas, VA, USA). The clinical isolate N6 was from the collection assembled for this study and originated from a typical COPD patient with respiratory tract colonization with both S. pneumoniae and Haemophilus influenzae, severe respiratory obstruction (GOLD score 3), two common comorbidities (hypertension and psychiatric disorders 33 -35 ), deep tobacco addiction and receiving Combivent w [a combination of fenoterol (a short-acting b 2 -agonist with properties similar to those of salbutamol) and ipratropium] as pre-admission treatment. All strains were grown on agar plates and MICs were determined by microdilution following the recommendations of the CLSI. 30 
Biofilm models
Naive and induced biofilms were obtained exactly as previously described.
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In brief: (i) 96-well plates were used as support and inoculated with 5×10 7 cfu/mL in cation-adjusted Mueller -Hinton broth supplemented with 5% lysed horse blood and 2% glucose; and (ii) naive biofilms were obtained by incubation for 2 -11 days and induced biofilms by starting with an inoculum of the supernatant (free bacteria) from a 6-day-old biofilm. Biofilms were cultivated in control medium or in medium supplemented with ipratropium (1.45 mg/L), salbutamol (7.25 mg/L), zanamivir (250 mg/L) or their combination. These concentrations were chosen for the following reasons: (i) for ipratropium or salbutamol, to mimic those expected in the epithelium lining fluid of patients upon single administration of these drugs by inhalation; and (ii) for zanamivir, to obtain maximal inhibition of NanA (see Text S1).
Biomass and bacterial viability quantifications
Bacterial viability was assessed by the reduction of resazurin to fluorescent resorufin and biomass was quantified by crystal violet staining as previously described.
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Antibiotic effect on biomass and viability (pharmacodynamic model) After 2 or 11 days of biofilm growth, culture media were removed and replaced with either fresh medium (negative control) or 1% SDS [to achieve complete bacterial killing and biomass solubilization (positive control)], or a medium supplemented with the antibiotic under study at concentrations ranging from 10 -4 to 10 3 times its MIC in broth. After 24 h, residual biomass and bacterial viability were quantified and expressed as percentages of a negative control (no antibiotic added).
18 Data were used to fit a Hill equation (sigmoid) as a function of the antibiotic concentration to determine: (i) relative maximal efficacy [E max (decrease in viability or biomass as a percentage of the control as extrapolated for an infinitely large antibiotic concentration)]; and (ii) relative potency [C 50 (concentration as a multiple of the MIC in broth yielding a 50% reduction of the signal measured in the absence of antibiotic)], two key pharmacological descriptors of the activity of antibiotics against biofilms.
Free sialic acid assay in biofilm supernatant Figure 1 . Kinetics of biofilm formation (biomass, as evaluated by crystal violet OD 570 ) by the reference capsulated strain ATCC 49619 (upper panels), the reference non-capsulated strain R6 (middle panels) and the clinical isolate N6 (lower panels), in the naive (left panels) and induced (right panels) models when cultured in control conditions (circles) or medium supplemented with 1.45 mg/L ipratropium (inverted triangles), 7.25 mg/L salbutamol (triangles) or the combination of ipratropium (1.45 mg/L) and salbutamol (7.25 mg/L) (squares). All values are means+SEM of 3 -26 experiments (each performed 12 times; when not visible, the SEM bars are smaller than the symbols). Data were used to fit a sigmoidal dose-response function whenever possible (broken straight lines are used when changes in OD 570 occurred abruptly). An inverted sigmoidal function (slope factor¼1) was used to describe the decrease in OD 570 observed between days 6 and 11 for the biofilm grown from strain N6 in the presence of the combination of ipratropium and salbutamol.
Release of sialic acid from S. pneumoniae by bacterial neuraminidase
Bacteria were incubated (3 h, 378C) in PBS, pH 7.4, with or without purified Arthrobacter ureafaciens a-(2 3,6,8,9)-neuraminidase (Sigma-Aldrich, St Louis, MO, USA) in the presence or absence of salbutamol, zanamivir or their combination. The released sialic acid was then quantified by the enzymatic assay described above.
Pharmacological agents
Ipratropium and salbutamol were obtained as the solutions used for nebulization in standard patient care and distributed for clinical use in Belgium (Atrovent w , Boehringer Ingelheim, Ingelheim am Rhein, Germany; and Ventolin w , GlaxoSmithKline, Genval, Belgium, respectively) and complying with the provisions of the European Pharmacopoeia. These solutions were diluted with culture medium to reach the appropriate concentrations needed for our experiments. Zanamivir was purchased from SigmaAldrich. Amoxicillin was obtained as the branded product for human parenteral use complying with the provisions of the European Pharmacopoeia (.90% purity) and distributed in Belgium as Clamoxyl w by GlaxoSmithKline s.a./n.v. (Genval, Belgium). Clarithromycin, moxifloxacin and solithromycin were obtained as microbiological standards (purity 100%) from Teva Pharmaceutical Industries (Petah Tikva, Israel), Bayer Schering Pharma AG (Berlin, Germany) and Cempra Pharmaceuticals (Chapel Hill, NC, USA), respectively. 
Curve fitting, correlations and statistical analyses
Results
Biofilm production by clinical isolates: relation to COPD severity and patient medications Naive biofilms were generated from all clinical strains and biomass was quantified after 10 days of culture in control medium. Results were stratified according to: (i) COPD severity upon admission (using GOLD scores 16 ); and (ii) patients' bronchodilator medication prior to hospitalization. No significant association between biomass amounts and GOLD scores was found but strains collected from patients who had received only muscarinic antagonists produced significantly less biomass than strains from patients who had received no treatment or other bronchodilator(s) (one-way ANOVA with Tukey's post test, P,0.05).
Influence of bronchodilators on biofilm formation from selected strains
Because no correlation between the rate of biofilm formation and the severity of patients' respiratory obstruction could be observed As previously shown, 18 biomass reached larger values over time in the induced than in the naive model for all three strains ( Figure 1 ). Of note, for the clinical strain, the intense growth Tables S3, S4 and S5 for strains ATCC 49619, R6 and N6, respectively).
obtained in the induced model at day 9 was followed by a precipitous loss of biomass at day 11, consistent with the well-known disassembly process leading to dissemination of the bacteria. 37 For the naive model, addition of ipratropium did not affect biomass increase up to day 8 but was subsequently associated with an almost complete loss of biomass at day 11 for all three strains. In the induced model, ipratropium: (i) also caused a precipitous loss of biomass at day 11 for the reference R6 strain; (ii) induced marked inhibition of biomass formation for the reference strain ATCC 49619 at day 7 and a loss of biomass subsequently;
and (iii) impaired the formation of biomass at day 9 and caused an almost complete loss of this biomass at day 11 for the clinical N6 strain. In sharp contrast, salbutamol did not have a marked effect on biomass over time compared with the control. The combination of ipratropium and salbutamol: (i) reduced the amount of biomass at day 11 for naive and induced biofilms obtained from strain ATCC 49619 and for naive biofilms obtained from strain R6; and (ii) caused a loss of biomass at day 10 for the naive biofilms and from day 8 for induced biofilms obtained from the clinical strain N6. Tables S3, S4 and S5 for strains ATCC 49619, R6, and N6, respectively).
Activity of amoxicillin, clarithromycin, moxifloxacin and solithromycin against biofilms grown in control conditions or in the presence of salbutamol combined with ipratropium
We first examined whether growing biofilms in the presence of the combination of salbutamol and ipratropium modified the activity of antibiotics with respect to both bacterial viability and biomass using the ATCC 49619 reference strain and both 2 day naive and 11 day induced biofilms (Figure 2 ). For amoxicillin and clarithromycin, only modest effects were observed with 2 day naive biofilms and no effect with 11 day induced biofilms. Conversely, moxifloxacin and solithromycin activities were markedly enhanced with respect to both E max and C 50 , especially if considering bacterial viability (for numerical data see Tables S3-S5 ). To check for absence of direct antibiotic effects of ipratropium or of salbutamol on S. pneumoniae, we measured the MICs of moxifloxacin and solithromycin in the presence of these bronchodilators at concentrations up to 4 and 8 mg/L, respectively, and saw no effect. Based on this first set of observations, only moxifloxacin and solithromycin were used in further studies.
Analysis of the changes in moxifloxacin and solithromycin activity against biofilms grown in the presence of ipratropium (alone) or salbutamol (alone or with zanamivir)
In the 11 day biofilm model (Figure 3a ), moxifloxacin completely suppressed the viability signal (reduction of resazurin) when biofilms developing from strain ATCC 49619, R6 or N6 had been grown in the presence of ipratropium alone compared with a maximal effect of only 50% in controls. This, interestingly enough, was even better than the result observed for the highly susceptible 2 day naive biofilms in non-supplemented medium (control; compare with Figure 2 ). Similar effects on biomass were observed for the reference ATCC 49619 and R6 strains, but to a much lesser extent for the clinical strain N6. Moreover, the C 50 of moxifloxacin was also improved by ipratropium. For solithromycin (Figure 3b ), growing biofilms in the presence of ipratropium exerted an effect that was qualitatively similar to that observed for moxifloxacin but quantitatively less marked. In contrast, growing biofilms in the presence of salbutamol alone was without marked effect on moxifloxacin or solithromycin activity against the 11 day induced biofilm, except for viability with the reference R6 strain (Figure 3a and b ). However, when tested in the 2 day induced model, salbutamol improved moxifloxacin and solithromycin killing activities against biofilms formed by the two reference strains, and this effect was blocked by zanamivir ( Figure 4 ). We checked that zanamivir (up to a concentration of 8 mg/L) did not modify the MIC for bacteria growing in broth. Tables S3-S5 and Figures S1-S6 show numerical data and graphical comparisons of the E max and C 50 values for each of the above conditions together with a statistical analysis of their differences.
Influence of biofilm pre-exposure to bronchodilators on sialic acid release in biofilm supernatant
Since biofilm cohesion depends on sialic acid-mediated intrabacterial bonds, 38 we checked whether the biomass decrease observed with biofilms grown in the presence of ipratropium and their increased susceptibility to antibiotics were associated with the release of free sialic acid in the medium. Figure 5 (left panel) shows the amount of sialic acid released in the medium of 11-day-old biofilms as a function of biofilm biomass. Sialic acid was released in larger amounts when biofilms had been grown in the presence of ipratropium, which was accompanied by a reduction in biomass for the two reference strains (ATCC 49619 and R6) compared with control conditions. For the clinical strain, N6, little sialic acid release was detected at day 11 because of the complete destructuring of the biofilm that had already been achieved earlier ( Figure 1 ) and had been accompanied by massive sialic acid release between days 2 and 7 (data not shown). Therefore, no association could be established between this release and biomass. Figure 5 (middle and right panels)
shows that this release of sialic acid was associated with a reduction in the viability of biofilms exposed to moxifloxacin and, to a lesser extent, to solithromycin for the two reference strains but not for the N6 strain.
Since we had observed that zanamivir completely abolished the effect of salbutamol on antibiotic efficacy (Figure 4) , we examined in more detail the changes in sialic acid release in biofilms exposed to salbutamol with and without zanamivir. Focusing first on 11 day biofilms (to compare with ipratropium), no clear correlation was seen between free sialic acid levels and biomass (Figure 6a ), partly because of high variability between strains. These were, therefore, examined individually for both 2-and 11-day-old biofilms and for naive and induced biofilms. . Correlation between maximal losses of viability (upper panels) and of biomass (lower panels) and biomass in 2 day and 11 day naive and induced biofilms formed from all three strains used in the study (reference strains ATCC 49619 and R6 and clinical strain N6) when grown in control medium (circles) or in the presence of 1.45 mg/L ipratropium (squares) or 7.25 mg/L salbutamol (triangles) and exposed to moxifloxacin (left panels) or solithromycin (right panel). The ordinate shows the antibiotic E max observed for each condition in the pharmacodynamic model (see Figures 3, S1, S3  and S5 and Tables S3, S4 and S5). The abscissa shows the amount of biomass as assessed by crystal violet staining (OD 570 ). The ellipses show the 95% probability area for each correlation (white, control medium; dark grey, ipratropium; light grey, salbutamol). Pearson correlation coefficients (r) and the corresponding probability values {P values [one tail, because there was no evidence of an inverse (positive) correlation]} were calculated considering the whole dataset in each panel.
Bronchodilators, antibiotics and biofilms acid release for biofilms formed by the reference strains (ATCC 49619 and R6) and that this increase was suppressed by zanamivir. For the clinical N6 strain, salbutamol only increased sialic acid release for the 2-day-old induced biofilm, and zanamivir exerted no or little effect.
Modulation of bacterial neuraminidase activity by salbutamol and zanamivir measured by sialic acid release from S. pneumoniae
Because the effects of salbutamol on sialic acid release and antibiotic activity were reversed by zanamivir, we examined whether salbutamol could directly modulate the activity of a purified neuraminidase against S. pneumoniae. Figure 7 shows the activity of neuraminidase against the three strains investigated in control conditions and in the presence of increasing concentrations of salbutamol, zanamivir and their combinations. Enzymatic activity was increased in the presence of salbutamol, with significant effects obtained at the concentration used in the biofilm experiments. Conversely, zanamivir reduced neuraminidase activity and also reversed the stimulating effect of salbutamol.
Discussion
To the best of our knowledge, this study demonstrates for the first time that culturing pneumococcal biofilms in the presence of two major and widely used bronchodilators markedly modulates their cohesion and their susceptibility to two antibiotics: moxifloxacin and solithromycin. In contrast, little effect was seen for amoxicillin and clarithromycin. The most striking results were observed with ipratropium, although those seen with salbutamol were not negligible. These are globally depicted in Figure 8 . Ipratropium and other choline analogues are known to interact with S. pneumoniae choline-binding proteins, including LytA amidase, LytC lysozyme and Pce phosphocholinesterase. 39 LytA and LytC play a critical role in pneumococcal attachment to epithelia, tissue colonization and biofilm formation. 31, 40 We show here that ipratropium exerts major effects on the matrix of aged biofilms accompanied or even preceded by a massive release of sialic acid, consistent with a process of biofilm disassembly. Our data strongly suggest that this disassembly contributes to the increased activity of moxifloxacin and, to a lesser extent, of solithromycin, probably by improving access of the antibiotics to bacteria. The lesser and even negligible effects of amoxicillin and clarithromycin that were observed during the first stages of our study could be related to the intrinsically poor activity of these antibiotics against S. pneumoniae biofilms.
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Moving now to salbutamol, the data suggest that it mainly acts through matrix remodelling mediated by the activation of neuraminidase, which may facilitate antibiotic diffusion. Indeed, zanamivir, known to inhibit pneumococcal NanA, 27 abolishes the release of sialic acid induced by salbutamol and its enhancing effect on antibiotic activity. Both the stimulatory effect of salbutamol and the inhibitory effect of zanamivir could be reproduced in vitro with purified neuraminidase. In S. pneumoniae, NanA contributes to biofilm formation by cleaving sialic acid residues from glycans and mucin at the epithelial cell surface, thus exposing host cell surface receptors for pneumococcal adherence. 32,41 -43 Sialic acid itself can also act as a signalling molecule, enhancing bacterial adherence to surfaces and/or survival within biofilms. 38 Moreover, sialic acid is present in the intercellular matrix of pneumococcal biofilms. 44 As sialylated moieties are present on or between bacteria, 45 the presence of free sialic acid in biofilm supernatants suggests a remodelling of the three-dimensional structure of the matrix and/or weakening of the interactions between bacteria during maturation.
Our study had three main limitations: (i) the small number of strains examined; (ii) the use of a single molecule as representative of each bronchodilator and antibiotic class; and (iii) the artificial nature of the support used for growing biofilms. Moreover, the effects of both ipratropium and salbutamol on antibiotic activity were less marked for biofilms formed from the clinical isolate, N6, compared with those formed from the two reference strains. This may have resulted from differences in matrix composition or three-dimensional structure, which are strain-and serotypedependent. 5, 44, 46 Moreover, the effects of salbutamol may also depend on the level of activity of NanA, which varies among serotypes, as described for other streptococcal species. 47 With respect to testing for additional bronchodilators, we unfortunately could not examine long-acting b 2 -agonists (e.g. salmeterol) or selective long-acting M2 -M3 muscarinic antagonists (e.g. tiotropium) because these compounds are sparingly water soluble (for details see Drug Bank, http://www.drugbank.ca/) and are unavailable as commercial solutions, making it difficult to use them in our in vitro model. In addition, we could not test for an effect of corticosteroids because we observed that budesonide, a typical inhaled corticosteroid, itself has an antibacterial effect on planktonic cells (with MICs of 3-6 mg/L), confirming literature data. 48 Our results as they are, however, clearly demonstrate the beneficial effect of ipratropium and, to some extent, salbutamol and their synergy with moxifloxacin and solithromycin. The observation that the two bronchodilators are not antagonists is of interest in this context. The marked effects seen with moxifloxacin may be related to the well-known intense bactericidal activity of this drug against S. pneumoniae. 49 It is tempting to speculate that the effects of moxifloxacin described here may at least partly explain why this antibiotic showed superiority to amoxicillin or clarithromycin for clinical cure, bacteriological eradication and long-term outcomes of AECBs in patients with COPD.
21 Similar clinical studies with solithromycin, which binds more tightly to the 50S ribosome subunit than clarithromycin, 50 would therefore be of great interest. In conclusion, we show here for the first time that ipratropium and salbutamol, which are used as first-line therapy in most COPD patients with AECBs, may act not only in vivo through their primary and well-known action of decreasing bronchial smooth constriction, but also by contributing to the elimination of the pneumococcal biofilm, as demonstrated here in vitro. These drugs may also improve the activity of at least two antibiotics of distinct pharmacological classes in killing bacteria encased in biofilms and reducing biofilm mass. Globally, the present data may help to further support and rationalize the current GOLD guidelines, which recommend combining antibiotics with short-acting bronchodilators for the treatment of bacterial exacerbations 16 in grade A patients (as first choice) or for all grades as alternative treatments. They may also pave the way for more rational searching and screening for add-on therapies for AECBs, which, due to their recurrent character and the damage they cause to the bronchial tree, are largely responsible for the progressive and irreversible decline in respiratory function of affected patients.
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